siRNA against Cbl-b and optionally IL2 and IL12 for use in the treatment of cancer

• Main Authors: LOIBNER, HANS, HASLINGER, ISABELLA, SEIDL, SANDRA, SCHUSTER, MANFRED, LAMETSCHWANDTNER, GUENTHER
• Format: Patent
• Language: English; French; German
• Published: 04.07.2012
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; VINEGAR; WINE

Use of Cbl-b inhibitor in a method of therapeutic treatment of a patient comprising the introduction of the Cbl-b inhibitor in natural killer (NK) cells of the patient, is claimed, where the NK cells are immune activated. Independent claims are included for: (1) immune activation of NK cells, comprising reducing or inhibiting the Cbl-b function in the NK-cells, preferably by administration of the Cbl-b inhibitor; and (2) a pharmaceutical composition comprising the Cbl-b inhibitor, and an additional NK cell activator. ACTIVITY : Cytostatic; Antimicrobial; Antiparasitic. MECHANISM OF ACTION : Cbl-b expression inhibitor; E3 ligase inhibitor. Die vorliegende Erfindung betrifft ein Verfahren zur Immunaktivierung von NK-Zellen durch Reduzierung oder Inhibierung der Cbl-b Funktion in den NK-Zellen. Dadurch wird das angeborene Immunsystem stimuliert wodurch die Therapie geeigneter Krankheiten ermöglicht wird.